Literature DB >> 11306683

Mutational analysis of the functional role of conserved arginine and lysine residues in transmembrane domains of the murine reduced folate carrier.

I G Sharina1, R Zhao, Y Wang, S Babani, I D Goldman.   

Abstract

The reduced folate carrier (RFC1) plays a major role in the delivery of folates into mammalian cells. RFC1 is an anion exchanger with seven conserved positively charged amino acid residues within 12 predicted transmembrane domains. This article explores the role of these residues in transport function by the development of cell lines in which arginines and lysines in RFC1 were replaced with leucine by site-directed mutagenesis. Three cell lines transfected with R131L, R155L, or R366L all lacked activity, despite high levels of protein expression in the plasma membrane, suggesting the crucial role of these amino acid residues in RFC1 function. In several mutant carriers, R26L, R42L, and K332L, there was little or no change in the influx K(t) value for MTX or influx K(i) value for folic acid. However, the R26L, R42L, and K332L carriers had decreased affinity for reduced folates. This was most prominent for K404L, which had 11- and 4-fold increases in influx K(i) for 5-methyl-THF and 5-formyl-THF, respectively, compared with L1210 cells. The marked influx stimulation observed with wild-type carrier when extracellular chloride was decreased was significantly diminished when influx was mediated by the K404L carrier, but was only slightly decreased with the R26L, R42L, and K332L mutants. This suggested that the K404 residue may be a major site of inhibition by chloride in the wild-type carrier. These studies indicate the important role that some positively charged residues within transmembrane domains of RFC1 play in RFC1 function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306683     DOI: 10.1124/mol.59.5.1022

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function.

Authors:  Heather Sadlish; Frederick M R Williams; Wayne F Flintoff
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

2.  Redesigning channel-forming peptides: amino acid substitutions that enhance rates of supramolecular self-assembly and raise ion transport activity.

Authors:  Lalida P Shank; James R Broughman; Wade Takeguchi; Gabriel Cook; Ashley S Robbins; Lindsey Hahn; Gary Radke; Takeo Iwamoto; Bruce D Schultz; John M Tomich
Journal:  Biophys J       Date:  2005-12-30       Impact factor: 4.033

3.  Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter.

Authors:  Larry H Matherly; Zhanjun Hou
Journal:  Vitam Horm       Date:  2008       Impact factor: 3.421

Review 4.  The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.

Authors:  Larry H Matherly; Mike R Wilson; Zhanjun Hou
Journal:  Drug Metab Dispos       Date:  2014-01-06       Impact factor: 3.922

Review 5.  Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.

Authors:  Zhanjun Hou; Larry H Matherly
Journal:  Curr Top Membr       Date:  2014       Impact factor: 3.049

6.  Characterization of a cysteine-less human reduced folate carrier: localization of a substrate-binding domain by cysteine-scanning mutagenesis and cysteine accessibility methods.

Authors:  Wei Cao; Larry H Matherly
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

7.  Oligomeric structure of the human reduced folate carrier: identification of homo-oligomers and dominant-negative effects on carrier expression and function.

Authors:  Zhanjun Hou; Larry H Matherly
Journal:  J Biol Chem       Date:  2008-11-19       Impact factor: 5.157

8.  Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition.

Authors:  Yijun Deng; Zhanjun Hou; Lei Wang; Christina Cherian; Jianmei Wu; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2008-01-08       Impact factor: 4.436

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.